Purpose <p>This review synthesizes the current evidence on time to surgery in breast cancer treatment, focusing on association with clinical outcomes, patient and system level factors associated with longer intervals, and strategies to minimize time to surgery.</p> Recent Findings <p>Observational studies of large national cohorts consistently demonstrate an interval of one to four months between diagnosis and surgery is associated with decreased overall and disease-free survival. Although the average time to surgery has increased over recent decades, it generally remains within two months. Notably, significant variations in time to surgery exist at the patient level, reflecting underlying systemic inequities.&#xa0;</p> Summary <p>While existing evidence suggests increased time to surgery may adversely affect overall survival, most patients receive surgical care within an acceptable timeframe. Persistent disparities related to race, socioeconomic status, and insurance coverage remain significant challenges. However, several promising interventions aimed at reducing time to surgery have been implemented with encouraging results.</p>